Literature DB >> 11526114

BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions.

P S Brzovic1, J E Meza, M C King, R E Klevit.   

Abstract

Cancer-predisposing missense mutations in the RING domain of BRCA1 primarily target Zn(2+)-liganding residues. Here we report on the structural consequences of such mutations introduced into the second Zn(2+) site (Site II) of the BRCA1 RING domain and their effect on the interaction with the BARD1 RING domain. Each of the BRCA1 Site II mutants still interact and form a stable heterodimer with BARD1. Limited proteolysis of BRCA1/BARD1 complexes, monitored by matrix-assisted laser desorption ionization time-of-flight spectrometry, show that the mutations cause a local structural perturbation that is primarily confined to the second Zn(2+) binding loop of the BRCA1 subunit. These findings are consistent with the structure of the BRCA1/BARD1 heterodimer, which shows this region is well removed from the helices required for dimerization with BARD1. Instead, the mutations alter a region of BRCA1 that appears to be required for interaction with ubiquitin-conjugating enzymes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526114     DOI: 10.1074/jbc.M106551200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Self-assembly properties of a model RING domain.

Authors:  Alex Kentsis; Ronald E Gordon; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

2.  Control of biochemical reactions through supramolecular RING domain self-assembly.

Authors:  Alex Kentsis; Ronald E Gordon; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

3.  Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.

Authors:  Peter S Brzovic; Jennifer R Keeffe; Hiroyuki Nishikawa; Keiko Miyamoto; David Fox; Mamoru Fukuda; Tomohiko Ohta; Rachel Klevit
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

4.  BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.

Authors:  Danièle Muller; Catherine Bonaiti-Pellié; Joseph Abecassis; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 5.  BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.

Authors:  Seth M Dever; E Railey White; Matthew C T Hartman; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

6.  BRIZ1 and BRIZ2 proteins form a heteromeric E3 ligase complex required for seed germination and post-germination growth in Arabidopsis thaliana.

Authors:  Mon Mandy Hsia; Judy Callis
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

7.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

8.  Correcting errors in the BRCA1 warning system.

Authors:  Yanping Liang; William J Dearnaley; Nick A Alden; Maria J Solares; Brian L Gilmore; Kevin J Pridham; A Cameron Varano; Zhi Sheng; Elizabeth Alli; Deborah F Kelly
Journal:  DNA Repair (Amst)       Date:  2018-11-22

9.  Understanding missense mutations in the BRCA1 gene: an evolutionary approach.

Authors:  Melissa A Fleming; John D Potter; Christina J Ramirez; Gary K Ostrander; Elaine A Ostrander
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

10.  Breast cancer gene variants: separating the harmful from the harmless.

Authors:  Susan M Domchek; Roger A Greenberg
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.